Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Dose Escalation and Expansion, Phase 1 Study to Evaluate the Tolerability, Safety and Pharmacokinetics of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

NCT06687941 is registered in ClinicalTrials.gov with Aptamer Sciences, Inc. as lead sponsor.

NCT NCT06687941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06687941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Dose Escalation and Expansion, Phase 1 Study to Evaluate the Tolerability, Safety and Pharmacokinetics of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Lead sponsor
Aptamer Sciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 11, 2025
Completion date
May 31, 2028
Enrollment
70 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular, carcinoma, non-small-cell lung, liver neoplasms, neoplasms